● TIER 1 — FDA-approved / recognizedGRADE AGH secretagogues & GH axis
Tesamorelin
GHRH analog. Research verification: Yes (TGA pending). 2 human study record(s) in the FitClinicMD studies database.
GOALS · Weight loss
FDA status
Approved: Egrifta SV/WR (HIV lipodystrophy).
Compounding (503A/503B)
Approved product; copies restricted.
DEA
Not controlled.
WADA (sport)
S2.2.4 GH-releasing factors: GHRH & analogues (CJC-1295, sermorelin, tesamorelin), GHS (ibutamoren, ipamorelin), GHRPs (GHRP-2/6, hexarelin)
Mechanism
Stabilized GHRH(1-44).
Human evidence · 2
n=61 HIV-NAFLD: liver fat reduction. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial.
n=412, 26 wk: VAT −15.2% vs +5.0%. Metabolic effects of a growth hormone-releasing factor in patients with HIV.
Reference only. This page summarizes publicly available regulatory and research information about Tesamorelin. It is not a prescription, an endorsement, or an offer to dispense, and regulatory status can change. Clinicians should verify current status before prescribing or compounding.